Generic medicines specialist Sandoz is to be listed on the SIX Swiss stock exchange as a fully independent entity on Wednesday after being spun-off by pharma giant Novartis.
This content was published on
2 minutes
Keystone-SDA
Novartis took the decision to spin off its subsidiary in August 2022, as part of its own transformation towards becoming a more focused pharmaceutical company.
Novartis shareholders get one Sandoz title for every five shares. The same breakdown applies to American Depositary Receipts (ADRs). A total of 431 million shares will be issued, and Sandoz will be listed from the start in the Swiss Leader Index (SLI), which includes the 30 biggest listings on the Zurich stock exchange.
Based on initial pre-market indications, Sandoz’s market capitalisation is likely to be a little under CHF20 billion ($21.7 billion). Novartis was worth CHF209 billion on Tuesday evening.
“Today marks the beginning of a new era for Sandoz as an independent company, but our goal remains unchanged: to be a pioneer in access to medicines for patients,” Sandoz chairman Gilbert Ghostine said in a press release.
Sandoz was founded in 1886, while the pharmaceutical company Novartis was created in 1996 via a merger with Ciba-Geigy. Initially just part of a division, Sandoz became an independent reporting unit in 2005.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.